Traumatic brain injury, CNS infectious diseases, Autoimmune encephalitis, Epilepsy, Chemical brain injury, Neurosurgery
Conditions
Interventions
Neuroimaging assessment including PET scans
Neuropsychological tests
Sponsors
National Institutes for Quantum Science and Technology
National Center for Neurology and Psychiatry, Brain Research Institute Niigata University, National Hospital Oganizetion Simofusa Psychiatric Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with traumatic brain injury, CNS infectious diseases, autoimmune encephalitis, epilepsy, chemical brain injury, or after neurosurgery. The diagnostic criteria for each disease shall be as follows Traumatic brain injury, CNS infectious diseases, autoimmune encephalitis, chemical brain injury: Patients with a history of traumatic brain injury, CNS infection, autoimmune encephalitis, or chemical brain injury confirmed by medical history Epilepsy: patients who meet the diagnostic criteria of the Epilepsy Clinical Practice Guidelines 2018 Patients who have undergone neurosurgery: those whose medical history confirms a history of neurosurgery Healthy volunteers Those who have the ability to give consent to participate in this study, and who can read and understand the consent explanatory document.
Exclusion criteria
Exclusion criteria: Patients group 1 Patients receiving dialysis 2 Patients who have or have had complications of serious physical diseases and are considered to be unsuitable for this study 3 Patients with severe claustrophobia 4 Pregnant, possibly pregnant, or lactating patients 5 Patients who are participating in other clinical trials, including clinical trials, research to which the Clinical Research Act applies or research to which ethical guidelines apply. 6 Patients within 3 months of blood donation 7 Allergic to local anesthetics or anticoagulants 8 Patients taking anticoagulants 9 Patients taking MAO-B inhibitors 10 Patients who regularly use health products with curcumin as an active ingredient 11 Patients who are unable to undergo MRI scanning 12 Others who are considered to be inappropriate as research subjects by the researcher Normal volunteers 1 Persons with a history of or complications from organic brain disease (disorders of consciousness, head trauma requiring hospitalizat cerebral hemorrhage, etc.) 2 Persons with substance-related disorders (drug dependence, etc.) 3 Persons undergoing dialysis 4 Persons who have or have had complications of serious physical diseases and are considered to be unsuitable for this study 5 Persons with severe claustrophobia 6 Pregnant, possibly pregnant, or lactating persons 7 Persons who are participating in other clinical trials, including clinical trials, research to which the Clinical Research Act applies, or research to which ethical guidelines apply. 8 Persons within 3 months of blood donation 9 Allergic to local anesthetics or anticoagulants 10 Persons taking anticoagulants 11 Persons taking MAO-B inhibitors 12 Persons who regularly use health products with curcumin as an active ingredient 13 Persons who are unable to undergo MRI scanning 14 Others who are considered to be inappropriate as research subjects by the researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Regional MAO-B density quantified by PET with 11C-SL25.1188 in patients and healthy volunteers | — |
Secondary
| Measure | Time frame |
|---|---|
| Regional tau accumulation quantified by PET with 18F-florzolotau in patients and healthy volunteers Quantity and distribution of tau pathology assessed by histopathology and autoradiography | — |
Countries
Japan
Contacts
Public ContactKeisuke Takahata
National Institutes for Quantum Science and Technology Advanced Neuroimaging Center, Institute for Quantum Medical Science
Outcome results
None listed